Cell Therapeutics (CTIC) Receives EU Approval for Pixuvri as Monotherapy to Treat Relapsed/Aggressive Non-Hodgkin B-Cell Lymphomas
Tweet
Share
E-mailGet Alerts CTIC Hot Sheet
Join SI Premium – FREE
Cell Therapeutics (Nasdaq: CTIC) announces Pixuvri approved in EU as monotherapy to treat adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-Cell Lymphomas.
The decision allows CTI to market Pixuvri in the 27 Member States of the EU as well as in Iceland, Liechtenstein and Norway. CTI expects to make Pixuvri immediately available in the EU, initially through a named patient program. CTI plans to market and commercialize Pixuvri with its own sales force in the EU starting in the 2nd half of 2012.
The decision allows CTI to market Pixuvri in the 27 Member States of the EU as well as in Iceland, Liechtenstein and Norway. CTI expects to make Pixuvri immediately available in the EU, initially through a named patient program. CTI plans to market and commercialize Pixuvri with its own sales force in the EU starting in the 2nd half of 2012.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Knorex discloses going concern note in annual report
- Gray Media closes $750M note offering to refinance higher-rate debt
- BIGG Digital Assets to rename as Surge Digital, consolidate shares
Create E-mail Alert Related Categories
Corporate News, Hot Corp. News, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
